Literature DB >> 23011590

Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.

Austin Duffy1, Fei Zhao, Lydia Haile, Jaba Gamrekelashvili, Suzanne Fioravanti, Chi Ma, Tamar Kapanadze, Kathryn Compton, William D Figg, Tim F Greten.   

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogenous population of cells comprising myeloid progenitor cells and immature myeloid cells, which have the ability to suppress the effector immune response. In humans, MDSC have not been well characterized owing to the lack of specific markers, although it is possible to broadly classify the MDSC phenotypes described in the literature as being predominantly granulocytic (expressing markers such as CD15, CD66, CD33) or monocytic (expressing CD14). In this study, we set out to perform a direct comparative analysis across both granulocytic and monocytic MDSC subsets in terms of their frequency, absolute number, and function in the peripheral blood of patients with advanced GI cancer. We also set out to determine the optimal method of sample processing given that this is an additional source of heterogeneity. Our findings demonstrate consistent changes across sample processing methods for monocytic MDSC, suggesting that reliance upon cryopreserved PBMC is acceptable. Although we did not see an increase in the population of granulocytic MDSC, these cells were found to be more suppressive than their monocytic counterparts.

Entities:  

Mesh:

Year:  2012        PMID: 23011590      PMCID: PMC6628699          DOI: 10.1007/s00262-012-1332-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Authors:  J Yan; C Tingey; R Lyde; T C Gorham; D K Choo; A Muthumani; D Myles; L P Weiner; K A Kraynyak; E L Reuschel; T H Finkel; J J Kim; N Y Sardesai; K E Ugen; K Muthumani; D B Weiner
Journal:  Cancer Gene Ther       Date:  2014-11-14       Impact factor: 5.987

Review 2.  Role of prostanoids in gastrointestinal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

Review 3.  Immunological off-target effects of standard treatments in gastrointestinal cancers.

Authors:  A G Duffy; T F Greten
Journal:  Ann Oncol       Date:  2013-11-07       Impact factor: 32.976

4.  Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.

Authors:  José Medina-Echeverz; Chi Ma; Austin G Duffy; Tobias Eggert; Nga Hawk; David E Kleiner; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Immunol Res       Date:  2015-01-30       Impact factor: 11.151

Review 5.  Molecular pathways: myeloid complicity in cancer.

Authors:  Ingunn M Stromnes; Philip D Greenberg; Sunil R Hingorani
Journal:  Clin Cancer Res       Date:  2014-07-21       Impact factor: 12.531

Review 6.  Immunosuppression associated with chronic inflammation in the tumor microenvironment.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Carcinogenesis       Date:  2015-09-08       Impact factor: 4.944

7.  Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.

Authors:  Kimberly R Jordan; Rodabe N Amaria; Oscar Ramirez; Eryn B Callihan; Dexiang Gao; Michelle Borakove; Elizabeth Manthey; Virginia F Borges; Martin D McCarter
Journal:  Cancer Immunol Immunother       Date:  2013-09-27       Impact factor: 6.968

8.  CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer.

Authors:  Dingzhi Wang; Haiyan Sun; Jie Wei; Bo Cen; Raymond N DuBois
Journal:  Cancer Res       Date:  2017-04-28       Impact factor: 12.701

9.  The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Authors:  David Agdashian; Mei ElGindi; Changqing Xie; Milan Sandhu; Drew Pratt; David E Kleiner; William D Figg; Julie A Rytlewski; Catherine Sanders; Erik C Yusko; Bradford Wood; David Venzon; Gagandeep Brar; Austin G Duffy; Tim F Greten; Firouzeh Korangy
Journal:  Cancer Immunol Immunother       Date:  2019-01-28       Impact factor: 6.968

10.  Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.

Authors:  Karolina Okła; Alicja Rajtak; Arkadiusz Czerwonka; Marcin Bobiński; Anna Wawruszak; Rafał Tarkowski; Wiesława Bednarek; Justyna Szumiło; Jan Kotarski
Journal:  J Transl Med       Date:  2020-06-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.